{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T19:49:55Z","timestamp":1662666595048},"reference-count":20,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.3892\/ol.2015.3591","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T07:01:19Z","timestamp":1439276479000},"page":"2662-2664","source":"Crossref","is-referenced-by-count":5,"title":["FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases"],"prefix":"10.3892","volume":"10","author":[{"given":"AYUMU","family":"MATSUOKA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"OSAMU","family":"MAEDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEGUMI","family":"INADA-INOUE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EIZABURO","family":"OHNO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHIKI","family":"HIROOKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUKIHIRO","family":"YOKOYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TSUTOMU","family":"FUJII","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASATO","family":"NAGINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDEMI","family":"GOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUICHI","family":"ANDO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"key20180108100236_b1-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180108100236_b2-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/02841860701666089","article-title":"Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature","volume":"47","author":"Hamberg","year":"2008","journal-title":"Acta Oncol"},{"key":"key20180108100236_b3-ol-0-0-3591","first-page":"1375","article-title":"A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan","volume":"38","author":"Sogabe","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"key20180108100236_b4-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12032-012-0361-2","article-title":"FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity","volume":"30","author":"Gunturu","year":"2013","journal-title":"Med Oncol"},{"key":"key20180108100236_b5-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase II study of FOLFIRINOX for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Okusaka","year":"2014","journal-title":"Cancer Sci"},{"key":"key20180108100236_b6-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2146\/ajhp120542","article-title":"Dysarthria induced by irinotecan in a patient with colorectal cancer","volume":"70","author":"Lee","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"key20180108100236_b7-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jnci\/91.7.647","article-title":"Irinotecan-induced central nervous system toxicity: a case report","volume":"91","author":"SevillaGarcia","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"key20180108100236_b8-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/jnci\/93.18.1419","article-title":"Irinotecan-induced dysarthria","volume":"93","author":"Baz","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"key20180108100236_b9-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0248-8663(02)00707-5","article-title":"Dysarthria during irinotecan administration","volume":"23","author":"Ceccaldi","year":"2002","journal-title":"Rev Med Interne"},{"key":"key20180108100236_b10-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/annonc\/mdh277","article-title":"Irinotecan chemotherapy associated with transient dysarthria and aphasia","volume":"15","author":"DeMarco","year":"2004","journal-title":"Ann Oncol"},{"key":"key20180108100236_b11-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jnci\/djj034","article-title":"Central nervous system toxicity induced by irinotecan","volume":"98","author":"Hamberg","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"key20180108100236_b12-ol-0-0-3591","first-page":"209","article-title":"Irinotecan-induced dysarthria: an insight into its pathogenesis?","volume":"2","author":"Gomez","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"key20180108100236_b13-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000336156","article-title":"Irinotecan-induced dysarthria","volume":"5","author":"Dressel","year":"2012","journal-title":"Case Rep Oncol"},{"key":"key20180108100236_b14-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1124\/mol.104.009944","article-title":"The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action","volume":"67","author":"Harel","year":"2005","journal-title":"Mol Pharmacol"},{"key":"key20180108100236_b15-ol-0-0-3591","first-page":"R939","article-title":"Hypoglossal and phrenic responses to cholinergic agents applied to ventral medullary surface","volume":"247","author":"Haxhiu","year":"1984","journal-title":"Am J Physiol"},{"key":"key20180108100236_b16-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0306-4522(84)90001-0","article-title":"Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: brainstem","volume":"12","author":"Cortes","year":"1984","journal-title":"Neuroscience"},{"key":"key20180108100236_b17-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180108100236_b18-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","article-title":"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicenter randomized phase III trial from the Hellenic oncology research group (HORG)","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"key20180108100236_b19-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20180108100236_b20-ol-0-0-3591","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy","volume":"132","author":"Park","year":"2009","journal-title":"Brain"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3591\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T12:01:16Z","timestamp":1515412876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,8,11]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.3892\/ol.2015.3591"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3591","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}